Efficacy and acceptability of needles 4 mm length in pediatric insulin therapy

Not Applicable

Active, not recruiting

• Conditions: type 1 diabetes; risk of intramuscolar insulin injection; Metabolic and Endocrine - Diabetes

• Registration Number: ACTRN12612000554864
• Lead Sponsor: AOU Meyer Children Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2012-05-24
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Active, not recruiting
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

type 1 diabetes

Exclusion Criteria

coeliac disease, thyroiditis, psichiatryc impairment, coagulation disease; HbA1c > 9,5% (except time of diagnosis)

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
average HbA1c from baseline, assessed by Siemens DCA Vantage Analizer[3,6,9, 12 months]

Secondary Outcome Measures

Name	Time	Method
Insulin/weight ratio, assessed on quarterly basis results of clinical examination and daily insulin requirements from glycemic diary[3, 6, 9, 12 months];Glycemic variability assessed by HBGI and LBGI evaluation of glucometer downloaded data (Accuchek SmartPix )[6, 12 months];Quality of life, assessed by Happy Face Rating Scale and Tuula-Maria Partanen questionnaire (Pract Diab Int april 2002 Vol. 19 No. 3)[6, 12 months]